About the Agency

The Medical Research Agency is a state institution responsible for the development of scientific research in the field of medical sciences and health sciences. MRA is an entity that is to create an innovative healthcare system. Its functioning will bring tangible benefits to patients - it will allow to assess which new medical technologies and therapeutic methods should be used to meet the needs of society.

MRA will conduct analytical activities in the field of assessment of decisions and their impact on the costs of functioning of the healthcare system. The analyzes will allow to present specific solutions thanks to which the healthcare system will be able to function in a more efficient way.

the development of medical sciences and health sciences and contributing to the growth of innovativeness of Polish medicine are the most important goals that have been set before the newly established Medical Research Agency, whose main role will be to provide funding for analyzes and clinical trials in healthcare.<.p>

Main directions of research

The Medical Research Agency was established to make better use of the potential for the development of medical research and health sciences in Poland, especially in the field of non-commercial clinical trials, which constitute approx. 1 percent of all registered research. In comparison, in the Western European countries this rate is around 40 percent. Ultimately, we want our research to reach 20-30 percent in our country.

The main direction of development of non-commercial clinical trials will be the search for new treatments in the most urgent areas of medicine: oncology and cardiology, as well as rare diseases. Because of the unprofitability these areas often remain beyond the interest of private companies. Providing patients with cancer, cardiac and rare diseases the possibilities of conducting clinical trials is essential for the entire healthcare system. In the future, it will result in access to modern drug therapies or reduction in the cost of treatment of selected diseases.

Research conducted by MRA will be used to evaluate the effectiveness and safety of medicines and technologies already used on the market, as well as exclusion from the system of those technologies that are ineffective. Checking the effectiveness of selected technologies in the conditions of the Polish healthcare system will make it easier for the authorities responsible for reimbursement and tariffs to make decisions in this respect.

The Agency will also support the development of population and epidemiological research in various areas of public health. The collected data will allow for the preparation of expert analyzes determining, for example, the causes of differentiation of incidence for specific diseases or mortality rates due to selected diseases in individual regions of Poland. The basis for their elaboration will not be, as before, general estimates, only their own national surveys.


The task of ABM will be to ensure proportional financing of medical sciences and health sciences in all relevant areas:

- basic research,

- research and development works,

- clinical trials of medicinal products and medical devices,

- epidemiological studies,

- management research,

- development and optimization of the healthcare system.

Until now, our system has a gap of not having a specialized institution responsible for conducting and supervising research in the field of medical science, which will be filled by the creation of the Agency.

Supporting medical research in the world

In the United States and most countries of the European Union there are specialized units financing research in the field of medical sciences and health sciences. The Medical Research Agency is built on the model of the best foreign agencies, such as the National Institutes of Health in the USA, the Medical Research Council in the United Kingdom or INSERM in France.

The National Institutes of Health, which was established in 1887, is an American government institution. Its basic tasks include supporting innovative research strategies to protect and improve health. It operates almost 30 institutions and centers, each of which has its own research program, often focusing on specific medical areas.

Clinical trials to improve human health are also conducted by the British Medical Research Council, closely cooperating with the National Health Service and the British health departments. The institution supports a broad spectrum of biomedical research - from basic laboratory science to clinical trials in all major disease areas.

A recognized institute of science and technology is the French INSERM, which monitors the work of nine thematic institutes involved in conducting research in selected areas of medicine, and cooperates with the most prestigious research centers from around the world.

The Innovative Medicines Initiative is a Belgian agency that works to accelerate the development of innovative medicines, with particular emphasis on those areas of public health in which the medical and social needs of patients are unmet. Institutes supporting the development of biomedical research work successfully in many other European countries, such as Denmark, Sweden, Finland or Ireland.

By bringing the Medical Research Agency into being, we want to create a native unit responsible for the development of scientific research in the field of medicine and health science in the country. The Agency will be responsible for cooperation with other international research centers and help Polish companies in the commercialization of Polish medical technologies.


Entities cooperating with MRA

In March this year The Medical Research Agency has signed a memorandum on cooperation in the development of clinical trials with the leading oncological center MD Anderson. The letter of intent provides for the creation of joint research and scientific programs and the conduct of joint clinical trials, with particular emphasis on non-commercial research. MD Anderson Cancer Center is one of the most respected global centers dedicated to the treatment of cancer.

The memorandum was signed by the minister of health, Łukasz Szumowski, acting as the president of the Medical Research Agency, dr. Radoslaw Sierpinski and MD Anderson vice-president George Wilding. Cooperation with MD Anderson is a great opportunity, thanks to which we will be able to develop clinical research in the field of oncology, which in turn will improve the quality of oncological care in Poland.


MD Anderson Center

The University of Texas MD Anderson Center employs 21 thousand people and the annual budget of the center exceeds $5 billion. Every year MD Anderson accepts almost 120,000 cancer patients. The center, which is part of the University of Texas, is today the largest cancer treatment center in the United States - it conducts around 1,000 clinical trials annually with around 10,000 participants. patients.

There is an Innovation Center at MD Anderson, whose goal is to eliminate cancer worldwide. Researchers are developing the latest generation of solutions in the field of new medical technologies, introducing new drugs and methods of diagnostics, designing medical devices and information solutions that can help in the care of oncological patients.